Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397639 · ClinicalTrials.gov registry record · Phase 3
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
A Phase 3 study of Agitation and Alzheimer's Type Dementia, sponsored by Suven Life Sciences Limited.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
- 20
- Study locations
NCT05397639 is a Phase 3 study of Agitation and Alzheimer's Type Dementia that is actively recruiting participants, run by Suven Life Sciences Limited. The registered enrollment target is 375 participants, above the 164-participant average among 8 other Agitation trials with a reported enrollment target (129% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05397639, a Phase 3 study of Agitation and Alzheimer's Type Dementia, is actively recruiting participants, sponsored by Suven Life Sciences Limited.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Masupirdine 50 mg
- DRUG Masupirdine 100 mg
Study Locations (20)
Florida
- Allied Biomedical Research Institute - Miami
- Central Miami Medical Institute - Miami
- CCM Clinical Research Group - Miami
- Miami Jewish Health - Miami
- Novel Clinical Research Center, LLC. - Miami
- Brainstorm Research - Miami
- Combined Research Orlando Phase I-IV - Orlando
- Quantum Laboratories Inc - Pompano Beach
California
- Advanced Research Center, Inc. - Anaheim
- ATP Clinical Research, Inc. - Costa Mesa
- Leading Edge Research LA, LLC - Encino
- Neuro Pain Medical Center - Fresno
- Neurology Center of North Orange County - Fullerton
- Mary S Easton Center for Alzheimer's Research and Care UCLA - Los Angeles
Illinois
- Re:Cognition Health - Chicago
- Insight Hospital and Medical Center Chicago - Chicago
New York
- Dent Neurologic Institute - Amherst
- Velocity Clinical Research, Syracuse - East Syracuse
Connecticut
- Ki Health Partners, LLC - Stamford
New Jersey
- Ocean Medical Research - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05397639
The ClinicalTrials.gov registry entry for NCT05397639 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 164-participant average among 8 other Agitation trials with a reported enrollment target (129% higher). The listed sponsor is Suven Life Sciences Limited, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Agitation appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05397639 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT05397639 about?
NCT05397639 is a clinical study titled "Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type". This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
What is the current status of trial NCT05397639?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2022-11-01. Estimated completion is 2026-12.
What conditions does trial NCT05397639 study?
This clinical trial studies the following conditions: Agitation, Alzheimer's Type Dementia.
What interventions are being tested in trial NCT05397639?
The interventions under investigation include: Placebo (DRUG), Masupirdine 50 mg (DRUG), Masupirdine 100 mg (DRUG).
Who is sponsoring clinical trial NCT05397639?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397639 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Agitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
RECRUITING · Phase 3
-
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
COMPLETED · Phase 3
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Neurosteer Bedside Monitoring System
RECRUITING · NA
-
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
RECRUITING · Phase 2
-
Life's End Benefits of cannaBidiol and tetrahYdrocannabinol
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.